reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxite plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid

Research output: Contribution to journalArticle

Abstract

cute promyelocytic leukemia (APL) is a variant of AML characterized by t (15; 17). The discovery of the molecular pathogenesis has led to the first targeted therapy for acute leukemia: all-trans retinoic acid (ATRA). ATRA is usually associated to anthracycline-based chemotherapy obtaining high response rates, but some potential longterm sequelae are described [1]. The introduction of arsenic trioxide (ATO)[2] and ATRA was compared to standard chemotherapy in a pivotal trial with excellent results both in terms of complete
Original languageEnglish
Pages (from-to)1328-1330
Number of pages3
JournalLEUKEMIA & LYMPHOMA
Publication statusPublished - 2019

Keywords

  • reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxite plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid

Fingerprint

Dive into the research topics of 'reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxite plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid'. Together they form a unique fingerprint.

Cite this